Treatment data

Creative Medical (CELZ) up 82% on stem cell treatment data

Shares of Creative Medical Technology Holdings, Inc. CELZ soared more than 80% after announcing key data from a two-year follow-up pilot study of StemSpine, a patented procedure for chronic lower back pain.

CELZ’s StemSpine treatment is an autologous procedure, using a patient’s own stem cells to treat lower back pain. Data from the two-year follow-up study demonstrated that treatment with the StemSpine procedure led to an 87% efficacy rate in treated patients without serious adverse effects.

Year-to-date, shares of Creative Medical Technology are up 33% against a 13.7% decline for the industry.

Image source: Zacks Investment Research

By management, StemSpine treatment offers a non-surgical option as well as a drug-free alternative to patients. The treatment is designed to inject the patient’s bone marrow aspirate into the areas surrounding the lower back to repair, reshape and improve circulation of blood vessels.

CELZ plans to present these data at the annual conference of the American Academy of Orthopedic Surgeons and also publish them in a peer-reviewed medical journal.

We note that Creative Medical Technology is engaged in treating multiple indications in urology and orthopedics using stem cell treatments. Besides StemSpine, CELZ currently markets two disposable kits, namely CaverStem and FemCelz.

CaverStem and FemCelz are autologous stem cell procedures, the former being used for the treatment of erectile dysfunction, while the latter is used to treat female sexual dysfunction.

Award from Creative Medical Technology Holdings, Inc.

Award from Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. Awards | Quote from Creative Medical Technology Holdings, Inc.

Zacks Ranking and Stocks to Consider

Creative Medical Technology currently carries a Zacks Rank #3 (Hold). Some higher ranked stocks in the same sector are Gamide cell GMDA, Nkarta NKTX and Vertex Pharmaceuticals VRTX, each carrying a Zacks Rank #2 (Buy) at present. You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Gamida Cell’s 2022 loss per share estimates have fallen from $1.35 to $1.17 in the past 30 days. GMDA shares are up 72.1% year-to-date.

Gamida Cell’s earnings beat estimates in three of the past four quarters, missing the mark in one, with the average surprise being 12.9%.

Nkarta’s per-share loss estimates for 2022 have fallen from $3.21 to $3.04 in the past 30 days. The same for 2023 fell from $3.97 to $3.20 in the last 30 days. Nkarta’s earnings beat estimates in two of the past four quarters and missed the target the other two times, with a negative surprise of 0.2%.

Vertex Pharmaceuticals earnings per share estimates for 2022 have fallen from $14.33 to $14.52 in the past 30 days. Shares of VRTX are up 13% year-to-date.

Earnings for Vertex Pharmaceuticals have exceeded estimates in each of the past four quarters, averaging 10%.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know our top 10 buy and hold tickers for all of 2022?

Last year 2021 Zacks Top 10 Stocks the portfolio generated gains as high as +147.7%. Now, a brand new portfolio has been selected from over 4,000 companies covered by the Zacks ranking. Don’t miss your chance to participate in this long term shopping

Access the Top 10 Zacks Stocks for 2022 today >>

Click to get this free report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

Gamida Cell Ltd. (GMDA): Free Stock Analysis Report

Nkarta, Inc. (NKTX): Free Stock Analysis Report

Creative Medical Technology Holdings, Inc. (CELZ): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.